Volume | 499,734 |
|
|||||
News | (1) | ||||||
Day High | 0.7715 | Low High |
|||||
Day Low | 0.70 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
PaxMedica Inc | PXMD | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.705 | 0.70 | 0.7715 | 0.7398 | 0.7042 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
2,107 | 499,734 | $ 0.7386924 | $ 369,150 | - | 0.372 - 29.75 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:57:29 | 85 | $ 0.73 | USD |
PaxMedica Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
5.48M | 7.41M | - | 0 | -18.29M | -2.47 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
PaxMedica News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PXMD Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.7329 | 0.85 | 0.677 | 0.7318781 | 463,803 | -0.0029 | -0.40% |
1 Month | 0.53 | 1.189 | 0.4011 | 0.7995751 | 7,251,600 | 0.20 | 37.74% |
3 Months | 0.5004 | 1.189 | 0.372 | 0.7833066 | 2,582,751 | 0.2296 | 45.88% |
6 Months | 5.5267 | 10.26 | 0.372 | 2.05 | 2,983,694 | -4.80 | -86.79% |
1 Year | 25.84 | 29.75 | 0.372 | 3.85 | 1,816,524 | -25.11 | -97.17% |
3 Years | 110.50 | 178.16 | 0.372 | 26.63 | 1,854,297 | -109.77 | -99.34% |
5 Years | 110.50 | 178.16 | 0.372 | 26.63 | 1,854,297 | -109.77 | -99.34% |
PaxMedica Description
PaxMedica Inc an early clinical stage biopharmaceutical company focusing on the development of anti-purinergic therapies (or APT), for the treatment of neurodevelopmental disorders, including autism spectrum disorder (or ASD), and Fragile X syndrome tremor-ataxia (or FXTAS). It focuses on the development and testing of its lead program, PAX-101, an intravenous formulation of suramin, in the treatment of ASD and FXTAS. It is also focused on the treatment of Human African Trypanosomiasis (or HAT). Its candidate PAX-102, proprietary intranasal formulation of suramin, as well as other new chemical entities that are more targeted and highly selective antagonists of particular purinergic receptor subtypes. |